DanCann Pharma was founded in 2018 and is a Danish pharmaceutical company. DanCann Pharma focuses on discovering, developing, manufacturing, and commercializing cannabinoid therapeutics in a broad range of disease areas. The company makes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Jeppe Krog Rasmussen | 9,10 | 9,10 | 2022-12-31 |
| Sellers of CannGros ApS | 7,85 | 7,85 | 2021-10-05 |
| Alexander Schoeneck | 6,21 | 6,21 | 2022-06-30 |
| Futur Pension | 5,56 | 5,56 | 2021-09-30 |
| Nordic Growth Opportunities 2 | 2,33 | 2,33 | 2023-09-26 |
| Morten Martinsen | 1,41 | 1,41 | 2021-12-30 |
| Hansen & Nytoft Invest Aps | 1,34 | 1,34 | 2021-08-19 |
| Tue Østergaard | 1,28 | 1,28 | 2022-12-31 |
| Vavi Invest Aps | 0,88 | 0,88 | 2021-08-19 |
| Carsten Trads | 0,63 | 0,63 | 2022-12-31 |
2023-11-30 Delårsrapport 2023-Q3